2005 Press Releases

Center for Urogynecology at Saint Barnabas Participates in Nationwide Clinical Trial of New Delivery Method For
Overactive Bladder

Livingston, N.J.—The Center for Urogynecology at Saint Barnabas is one of only 40 sites nationally to participate in a new clinical trial to assess the effectiveness of a new delivery method of an approved medication for treatment of overactive bladder.

“We are please to participate in any research that addresses this common condition that affects more than 33 million Americans, 75 percent of whom are female,” says Jeffrey Segal, M.D., Director of the Center for Urogynecology at Saint Barnabas.

In the clinical trial, patients will be given oxybutynin, a medication used for more than 30 years to treat this condition. The study will assess a new delivery method of this already approved drug.

Overactive bladder involves a need to get to the bathroom quickly to avoid an accident. In addition to feelings of urgency, the condition is usually accompanied by frequent urination, even at night. About forty percent of people with this condition experience wetting accidents.

If you are a woman with overactive bladder or incontinence you may qualify for the new research study. Women who qualify to participate will receive all study-related care at no charge, including physician visits, study medication, and lab services. Compensation of $500 a participant is offered.

Qualified women must:

• Be diagnosed over six months ago with overactive bladder or incontinence
• Have a history of urine leakage
• Have sudden and frequent urges to urinate
• Be in general good health

For more information call, please call The Center for Urogynecology at
(973) 322-9998. The Center specializes in the treatment of pelvic organ prolapse, urinary incontinence, overactive bladder symptoms, voiding dysfunction, lower urinary tract and rectovaginal fistulas, fecal incontinence, chronic pelvic pain, including interstitial and other urogynecologic problems.

Date: February 4, 2005

[ top ]